Metabolic complications associated with HIV protease inhibitor therapy (Q35592375)

9 August 2017

1 reference

title

Metabolic complications associated with HIV protease inhibitor therapy (English)

1 reference

9 August 2017

David Nolan

1

1 reference

9 August 2017

publication date

1 January 2003

1 reference

9 August 2017

1 reference

9 August 2017

volume

63

1 reference

9 August 2017

issue

23

1 reference

9 August 2017

page(s)

2555-2574

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200363230-00001

9 August 2017

exact match

0 references

cites work

Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome

1 reference

12 December 2020

Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy

1 reference

12 December 2020

Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.

1 reference

12 December 2020

Atherogenicity of triglyceride-rich lipoproteins

1 reference

12 December 2020

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

12 December 2020

Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis

1 reference

12 December 2020

Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection

1 reference

12 December 2020

Apoprotein c-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy

1 reference

12 December 2020

Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection

1 reference

12 December 2020

Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy

1 reference

12 December 2020

Insulin resistance, impaired postprandial lipid metabolism and abdominal obesity. A deadly triad

1 reference

12 December 2020

Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

1 reference

12 December 2020

Protease inhibitor-associated hyperinsulinaemia

1 reference

12 December 2020

Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy

1 reference

12 December 2020

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

1 reference

12 December 2020

Indinavir induces acute and reversible peripheral insulin resistance in rats.

1 reference

12 December 2020

Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: clinical aspects

1 reference

12 December 2020

Vascular and lipid syndromes in selected HIV-infected patients

1 reference

12 December 2020

Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance.

1 reference

12 December 2020

Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) family study

1 reference

12 December 2020

Vascular complications associated with use of HIV protease inhibitors

1 reference

12 December 2020

Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action

1 reference

12 December 2020

The mechanism of insulin resistance caused by HIV protease inhibitor therapy.

1 reference

12 December 2020

Insulin resistance in HIV protease inhibitor-associated diabetes

1 reference

12 December 2020

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

1 reference

12 December 2020

An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses

1 reference

12 December 2020

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

1 reference

12 December 2020

Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile

1 reference

12 December 2020

Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance

1 reference

12 December 2020

Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients.

1 reference

12 December 2020

Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study

1 reference

12 December 2020

Coronary artery disease occurring with protease inhibitor therapy

1 reference

12 December 2020

Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia

1 reference

12 December 2020

Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial

1 reference

12 December 2020

Visceral abdominal-fat accumulation associated with use of indinavir

1 reference

12 December 2020

Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution.

1 reference

12 December 2020

Hypertrophy of the breasts in a patient treated with indinavir

1 reference

12 December 2020

Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus

1 reference

12 December 2020

Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis

1 reference

12 December 2020

Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?

1 reference

12 December 2020

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

12 December 2020

Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations

1 reference

12 December 2020

Cell-mediated immunity in atherosclerosis.

1 reference

12 December 2020

Another case of breast hypertrophy in a patient treated with indinavir

1 reference

12 December 2020

Genetics of lipoprotein disorders

1 reference

12 December 2020

Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction

1 reference

12 December 2020

Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients

1 reference

12 December 2020

Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations

1 reference

12 December 2020

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

1 reference

12 December 2020

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

Influence of protease inhibitor therapy on lipoprotein metabolism.

1 reference

12 December 2020

Severe premature coronary artery disease with protease inhibitors

1 reference

12 December 2020

Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial

1 reference

12 December 2020

Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.

1 reference

12 December 2020

ADD-1 provides major new insight into the mechanism of insulin action

1 reference

12 December 2020

The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes

1 reference

12 December 2020

Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor

1 reference

12 December 2020

Diet and risk of coronary heart disease and type 2 diabetes

1 reference

12 December 2020

Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors

1 reference

12 December 2020

A comparison of the prevalence of the metabolic syndrome using two proposed definitions

1 reference

12 December 2020

Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients

1 reference

12 December 2020

Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.

1 reference

12 December 2020

"Buffalo hump" in men with HIV-1 infection.

1 reference

12 December 2020

Metabolic basis of HIV-lipodystrophy syndrome

1 reference

12 December 2020

Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes

1 reference

12 December 2020

"Buffalo hump" in HIV-1 infection

1 reference

12 December 2020

Indinavir-associated lipodystrophy.

1 reference

12 December 2020

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

12 December 2020

Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy

1 reference

12 December 2020

Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines

1 reference

12 December 2020

Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients

1 reference

12 December 2020

Vascular complications associated with use of HIV protease inhibitors

1 reference

12 December 2020

Switching effective antiretroviral therapy: a review.

1 reference

12 December 2020

T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1

1 reference

12 December 2020

Standards of medical care for patients with diabetes mellitus

1 reference

12 December 2020

Myocardial infarction in HIV-infected men receiving protease inhibitors

1 reference

12 December 2020

HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia

1 reference

12 December 2020

Hypertriglyceridemia in the acquired immunodeficiency syndrome

1 reference

12 December 2020

Marked hyperlipidaemia on ritonavir therapy

1 reference

12 December 2020

Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways

1 reference

12 December 2020

Lipid changes in HIV-infected patients who started rescue therapy with an amprenavir/ritonavir-based highly active antiretroviral therapy

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

12 December 2020

Severe diabetes associated with protease inhibitor therapy

1 reference

12 December 2020

Fat accumulation and HIV-1 protease inhibitors

1 reference

12 December 2020

Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study

1 reference

12 December 2020

Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution

1 reference

12 December 2020

Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors.

1 reference

12 December 2020

Vascular complications associated with use of HIV protease inhibitors

1 reference

12 December 2020

Benign symmetric lipomatosis associated with protease inhibitors

1 reference

12 December 2020

Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome

1 reference

12 December 2020

Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients

1 reference

12 December 2020

Atherosclerosis — An Inflammatory Disease

1 reference

12 December 2020

The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance

1 reference

12 December 2020

Lipid evaluation in HIV-1-positive patients treated with protease inhibitors

1 reference

12 December 2020

Protease inhibitors, diabetes mellitus and blood lipids

1 reference

12 December 2020

Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy

1 reference

12 December 2020

Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment?

1 reference

12 December 2020

Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations

1 reference

12 December 2020

Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients?

1 reference

12 December 2020

Disorders of fat distribution in HIV infection

1 reference

12 December 2020

Protease inhibitor-associated hyperglycaemia

1 reference

12 December 2020

Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART).

1 reference

12 December 2020

Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism

1 reference

12 December 2020

New-onset diabetes mellitus associated with use of protease inhibitor

1 reference

12 December 2020

Abnormal fat distribution and use of protease inhibitors

1 reference

12 December 2020

T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein

1 reference

12 December 2020

Localized adipose tissue hypertrophy in patients receiving human immunodeficiency virus protease inhibitors

1 reference

12 December 2020

Lipodystrophia with protease inhibitors in HIV patients

1 reference

12 December 2020

Molecular basis of partial lipodystrophy and prospects for therapy

1 reference

12 December 2020

Hyperlipidemia associated with protease inhibitor therapy

1 reference

12 December 2020

Vascular complications associated with use of HIV protease inhibitors

1 reference

12 December 2020

Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy

1 reference

12 December 2020

Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy

1 reference

12 December 2020

Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapy

1 reference

12 December 2020

Abnormal fat distribution and use of protease inhibitors

1 reference

12 December 2020

Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

1 reference

12 December 2020

Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART).

1 reference

12 December 2020

Hyperlipidemia under treatment with proteinase inhibitors

1 reference

12 December 2020

Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy.

1 reference

12 December 2020

Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection

1 reference

12 December 2020

Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events

1 reference

12 December 2020

Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus.

1 reference

12 December 2020

Metabolic effects of indinavir in healthy HIV-seronegative men

1 reference

12 December 2020

Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study.

1 reference

12 December 2020

10.2165/00003495-200363230-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

9 August 2017

1010522070

0 references

1 reference